Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 20/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 20/20 | 0.54 |
| ▸ | CDK2 | P24941 | 20/20 | 0.54 |
| ▸ | CDK4 | P11802 | 15/20 | 0.51 |
| ▸ | CCND1 | P24385 | 15/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 12/20 | 0.51 |
| ▸ | CDK1 | P06493 | 12/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 12/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 12/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6993959 | 0.85 | CCNE2 (0.50) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6999205 | 0.84 | CCNE2 (0.48) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6991451 | 0.84 | CCNE2 (0.46) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6997188 | 0.84 | CCNE2 (0.52) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6997368 | 0.81 | CCNE2 (0.51) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL1960096 | 0.81 | PDE2A (0.42) | CCNE2CCNE1CDK2 | |
| SCHEMBL6993028 | 0.81 | PDE2A (0.47) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL6999184 | 0.79 | PDE2A (0.57) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7896916 | 0.78 | CCNE2 (0.55) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL7442300 | 0.77 | PDE2A (0.57) | CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973774-B1 | 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES | BAYER AG (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-6174884-B1 | CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |